Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human WT1 Antibodies:
anti-Rat (Rattus) WT1 Antibodies:
anti-Mouse (Murine) WT1 Antibodies:
Go to our pre-filtered search.
Human Monoclonal WT1 Primary Antibody for IHC, IHC (fro) - ABIN258719
Rauscher, Morris, Fredericks, Lopez-Guisa, Balakrishnan, Jost, Herlyn, Rodeck: Characterization of monoclonal antibodies directed to the amino-terminus of the WT1, Wilms' tumor suppressor protein. in Hybridoma 1998
Show all 5 Pubmed References
Human Polyclonal WT1 Primary Antibody for CyTOF, FACS - ABIN4899232
Da Sacco, Lemley, Sedrakyan, Zanusso, Petrosyan, Peti-Peterdi, Burford, De Filippo, Perin: A novel source of cultured podocytes. in PLoS ONE 2013
Show all 3 Pubmed References
Human Monoclonal WT1 Primary Antibody for FACS, IF - ABIN5590995
Rauscher: The WT1 Wilms tumor gene product: a developmentally regulated transcription factor in the kidney that functions as a tumor suppressor. in FASEB journal : official publication of the Federation of American Societies for Experimental Biology 1993
Mouse (Murine) Polyclonal WT1 Primary Antibody for IHC, IHC (p) - ABIN441321
Husain, Ginawi, Bashir, Kfoury, Al Johani, Hagar, Raddaoui, Al Ghonaim, Alsuwaida: Focal and segmental glomerulosclerosis in murine models: a histological and ultrastructural characterization with immunohistochemistry correlation of glomerular CD44 and WT1 expression. in Ultrastructural pathology 2018
Human Polyclonal WT1 Primary Antibody for ELISA, WB - ABIN547718
Rao, Pham, Imam, MacLean, Murali, Furuta, Sinha-Hikim, Wilkinson: Tissue-specific RNAi reveals that WT1 expression in nurse cells controls germ cell survival and spermatogenesis. in Genes & development 2006
In an Asian setting, PAX8 and WT1 are expressed in the vast majority of serous ovarian cancers and may be useful in distinguishing serous ovarian carcinomas from other poorly differentiated tumours.
Wilms' tumor 1 mRNA expression: a good tool for differentiating between myelodysplastic syndrome and aplastic anemia in children.
The WT1 gene expression level at diagnosis can be used as an unfavorable prognostic factor for AML patients with NPM1 or FLT3-ITD wild types
The results illustrated the therapeutic association of these two commercial FDA-approved drugs in (WT1) transcriptional down-regulation. Since (WT1) has known as a transcriptional regulator of at least 137 target genes, so the new data are significant for the development of new approaches to regulating WT1 and other target genes by employing special drugs in cancer treatment.
These findings demonstrate that genetic polymorphisms in the WT1 gene in subjects of European ancestry are associated with interindividual differences in rubella virus-specific cellular immunity after measles-mumps-rubella II vaccination.
Slow progression nephropathy was observed in Denys-Drash syndrome patients. Missense mutation was the most common type of WT1 variants, followed by splice mutation in this group of patients. Early onset nephropathy, rapid progression and glomerular basement membrane layering were observed in patients with splice mutation.
this study investigates the role of WT1 rs16754 polymorphism in acute myeloid leukemia.
urinary exosomal WT1 mRNA is a useful biomarker to improve risk stratification in patients with diabetic nephropathy
WT1 expression level could be a useful genetic marker for routine clinical work in acquired bone marrow failure syndromes.
inflammatory cytokineinduced WT1 overexpression may promote the formation of psoriatic skin lesions via regulation of the proliferation and apoptosis of keratinocytes.
BRG1, the essential ATPase subunit of the SWI/SNF chromatin-remodelling complex, is required for expression of Wilms' tumour 1 (Wt1), fetal epicardium-derived cell activation and subsequent differentiation into coronary smooth muscle, and restoration of Wt1 activity upon myocardial infarction.
Study shows that WT1 expression in breast cancer (BC) occurs at low frequency. Also, the results demonstrate that WT1 plays a role in regulating the epithelial-mesenchymal balance of BC cells and that WT1-expressing tumors are mainly associated with a mesenchymal phenotype. WT1 gene expression also correlates with CYP3A4 levels and is associated with poor response to taxane treatment.
Study provides evidence that the renal specific phenotype of nail patella-like renal disease associated with LMX1B R246Q mutation may be due to dominant negative effect on WT1(- KTS) specific isoforms causing a disruption of the WT1 isoform ratio and subsequent decrease in key podocyte related genes.
MDS and acute myeloid leukemia were the major target diseases to provide proof of concept for the therapeutic potential of the WT1 peptide vaccine. WT1 vaccination-induced clinical responses or usefulness were also shown for chronic myeloid leukemia, multiple myeloma, and acute lymphoblastic leukemia, as well as various types of solid cancers. Non-Hodgkin's lymphoma and myeloproliferative neoplasms may be target diseases
Total heterogeneous methylation of WT1 conferred a significantly higher risk of Colorectal Cancer.The gene methylation status of blood leukocytes may be associated with CRC risk.
excessive expression of WT1 was detected in ovaries of Polycystic Ovary Syndrome patients providing novel insights into the relationship between hyperandrogenism and polycystic ovaries of PCOS and WT1.
WT1 isoforms containing or lacking an insert, KTS, between zinc finger 3 and 4 have different binding patterns to both DNA and RNA targets in acute myeloid leukemia. (Review)
study identifies a novel mechanism of hepatocellular carcinoma inhibition through beta-catenin-independent Wnt signalling, which is regulated by WT1-associated LEF1 repression. The study also highlights mangiferin as a promising Wnt inhibitor for HCC treatment.
our data demonstrate that WT1 protein undergoes proteolytic processing by caspase-3 in chemotherapeutic drugs-induced apoptosis. This processing is associated with a reduction of WT1 protein.
WT1 reduces malignancy of malignant mesothelioma cell lines and might be a new molecular target in mesothelioma therapy
WT1 interference with Wnt signaling represents an important mode of its action relevant to the suppression of tumor growth and guidance of development.
Dynamical and context-specific expression profile of WT1 in these organs occurs during their development, implying its close association with the development and function of porcine kidney, ovary and testis.
Sodium butyrate-induced hyperacetylation up-regulates WT1 expression in porcine kidney fibroblasts, suggesting the involvement of histone acetylation in the transcriptional modulation of WT1 in porcine kidney cells.
Results indicate that WT1 plays important roles in the development of porcine preimplantation embryos, but not in oocyte maturation.
WT1 is expressed in porcine fetal fibroblasts, but the levels of expression were much lower compared to porcine primary kidney fibroblasts and swine testis, and WT1 is essential for the maintenance of development and survival of porcine fetal fibroblasts
Study summarizes the different roles of WT1b gene in the embryonic zebrafish kidney and the adult kidney as well. [review]
While wt1a has a more fundamental and early role in pronephros development and is essential for the formation of glomerular structures, wt1b functions at later stages of nephrogenesis.
We propose that WT1 modulates through the RALDH2/retinoic acid axis the restabilization of a part of the pancreatic stellate cell population and, indirectly, the repair of the pancreatic architecture, since quiescent pancreatic stellate cells are required for pancreas stability and repair.
results reveal an important role for the WT1 tumor suppressor gene in the response to DNA damage
Loss of Wt1 in mature podocytes modulates podocyte Notch activation, which could mediate early events in WT1-related glomerulosclerosis.
WT1 expression is not essential for pancreas development, although it influences intestinal rotation and correct localization of the dorsal pancreas within the mesogastrium.
WT1 expression in CoRL is important for the glomerular response to damage. When WT1 is selectively deleted in CoRL in the setting of podocyte loss, their proliferation and migration to the glomerulus, and to some extent their transdifferentiation toward a podocyte fate through MET changes, are markedly reduced.
this study shows that WT1 ameliorates podocyte injury via repression of EZH2/beta-catenin pathway in diabetic nephropathy
both the local oxygen environment and WT1, which enhances KDR expression, contribute to sex-specific Sox9 expression in developing murine gonads
The authors show that the posthepatic mesenchymal plate coelomic epithelium gives rise to a mesenchyme that populates the pleuroperitoneal folds isolating the pleural cavities before the migration of the somitic myoblasts. This process fails when Wt1 is deleted from this area.
Study reveals a novel role for Wt1 in early mammalian development and identifies proteases as critical mediators of the maternal-embryonic interaction. Data also suggest that the role of Wt1 in regulating fertility is conserved in mammals.
WT1 is required for the lineage specification of both Sertoli and granulosa cells by repressing Sf1 expression. Without Wt1, the expression of Sf1 was upregulated and the somatic cells differentiated into steroidogenic cells instead of supporting cells.
study provides novel insights into the role of WT1 and GATA4 during the sex differentiation phase and represents an approach that can be applied to assess other proteins with as yet unknown functions during gonadal development
WT1 regulates reporter gene expression through interaction with 3' UTR-binding sites
These results indicate that Osr1 and Wt1 act synergistically to regulate nephron endowment by controlling metanephric mesenchyme specification during early nephrogenesis.
Wt1 regulates the development of FLC.
WT1 stimulates IGFBP5 transcription in developing murine kidney.
Over expression of miR-206 promotes podocyte injury via downregulation of WT1, which provides a new pathogenic mechanism for Focal segmental glomerulosclerosis and miR-206 may be a potential therapeutic target.
by targeting WT1, miR743a suppresses the proliferation of MM cells in vitro, and probably possesses vital functions in kidney development and kidneyassociated diseases.
To test the tumorigenic potential of different cell types in the developing kidney, we used kidney progenitor-specific Cre recombinase alleles to introduce Wt1 and Ctnnb1 mutations, two alterations observed in Wilms tumor, into embryonic mouse kidney, with and without biallelic Igf2 expression, another alteration that is observed in a majority of tumors
miR-125a is a regulatory molecule that suppresses WT1 expression via a direct interaction with the 3'UTR of WT1 mRNA and miR-125a knockout mice induce myeloproliferative disease (MPD) and urogenital abnormalities
The analysis presented here demonstrates that WT1 regulates a broad set of genes, and almost 50% of the top 200 podocyte-specific genes-as defined in the GUDMAP gene expression atlas-were bound by WT1.
This gene encodes a transcription factor that contains four zinc-finger motifs at the C-terminus and a proline/glutamine-rich DNA-binding domain at the N-terminus. It has an essential role in the normal development of the urogenital system, and it is mutated in a small subset of patients with Wilm's tumors. This gene exhibits complex tissue-specific and polymorphic imprinting pattern, with biallelic, and monoallelic expression from the maternal and paternal alleles in different tissues. Multiple transcript variants have been described. In several variants, there is evidence for the use of a non-AUG (CUG) translation initiation site upstream of and in-frame with the first AUG. Authors of PMID:7926762 also provide evidence that WT1 mRNA undergoes RNA editing in human and rat, and that this process is tissue-restricted and developmentally regulated.
Wilms tumor protein
, amino-terminal domain of EWS
, last three zinc fingers of the DNA-binding domain of WT1
, Chick Wilm's tumour protein
, Wilms tumor 1
, Wilms tumor protein homolog A
, Wilms tumor protein homolog
, Wilms tumor suppressor protein 1b
, Wilm's tumor suppressor
, Wilms tumor protein homolog B